Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis

The goal of this clinical trial is to find out how the study drug HHK001 compares to Enantone (an approved treatment for endometriosis) when given as a single 3.75 mg injection to participants with endometriosis. Both products contain the same active ingredient: leuprorelin acetate. We will check how the body absorbs and responds to each medicine, monitor possible side effects and treatment benefits. Researchers will compare HHK001 to Enantone to test the advantages of its updated formulation.

NCT Number	NCT07755956
Lead Sponsor	Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Conditions	Endometriosis
Enrollment	30 participants
Start Date	2026-08-31
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-10